Cullinan Oncology Net Worth
Cullinan Oncology Net Worth Breakdown | CGEM |
Cullinan Oncology Net Worth Analysis
Cullinan Oncology's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cullinan Oncology's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cullinan Oncology's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cullinan Oncology's net worth analysis. One common approach is to calculate Cullinan Oncology's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cullinan Oncology's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cullinan Oncology's net worth. This approach calculates the present value of Cullinan Oncology's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cullinan Oncology's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cullinan Oncology's net worth. This involves comparing Cullinan Oncology's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cullinan Oncology's net worth relative to its peers.
Enterprise Value |
|
To determine if Cullinan Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cullinan Oncology's net worth research are outlined below:
| Cullinan Oncology generated a negative expected return over the last 90 days | |
| Cullinan Oncology has high historical volatility and very poor performance | |
| Net Loss for the year was (167.57 M) with profit before overhead, payroll, taxes, and interest of 18.94 M. | |
| Cullinan Oncology LLC currently holds about 611 M in cash with (145.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cullinan Oncology has a poor financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Cullinan Oncology stock hits 52-week low at 8.35 - Investing.com |
Cullinan Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cullinan Oncology LLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cullinan Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Cullinan Oncology Target Price Consensus
Cullinan target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Cullinan Oncology's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Strong Buy |
Most Cullinan analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Cullinan stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Cullinan Oncology LLC, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCullinan Oncology Target Price Projection
Cullinan Oncology's current and average target prices are 8.52 and 33.00, respectively. The current price of Cullinan Oncology is the price at which Cullinan Oncology LLC is currently trading. On the other hand, Cullinan Oncology's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Cullinan Oncology Market Quote on 23rd of March 2025
Target Price
Analyst Consensus On Cullinan Oncology Target Price
Know Cullinan Oncology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cullinan Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cullinan Oncology LLC backward and forwards among themselves. Cullinan Oncology's institutional investor refers to the entity that pools money to purchase Cullinan Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rtw Investments, Llc | 2024-12-31 | 1.7 M | Vr Adviser, Llc | 2024-12-31 | 1.4 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.3 M | Kynam Capital Management, Lp | 2024-12-31 | 1.3 M | Geode Capital Management, Llc | 2024-12-31 | 1.2 M | Siren, L.l.c. | 2024-12-31 | 1.2 M | Braidwell Lp | 2024-12-31 | 1.2 M | Nextech Invest Ag | 2024-12-31 | 1.1 M | Adage Capital Partners Gp Llc | 2024-12-31 | 1 M | Mpm Oncology Impact Management Lp | 2024-12-31 | 7.6 M | Bvf Inc | 2024-12-31 | 5.8 M |
Follow Cullinan Oncology's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 510.23 M.Market Cap |
|
Project Cullinan Oncology's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.28) | (0.30) | |
| Return On Capital Employed | (0.38) | (0.36) | |
| Return On Assets | (0.28) | (0.30) | |
| Return On Equity | (0.39) | (0.37) |
When accessing Cullinan Oncology's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cullinan Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cullinan Oncology's profitability and make more informed investment decisions.
Evaluate Cullinan Oncology's management efficiency
Cullinan Oncology LLC has return on total asset (ROA) of (0.2226) % which means that it has lost $0.2226 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.321) %, meaning that it created substantial loss on money invested by shareholders. Cullinan Oncology's management efficiency ratios could be used to measure how well Cullinan Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of March 2025, Return On Tangible Assets is likely to drop to -0.3. In addition to that, Return On Capital Employed is likely to grow to -0.36. At this time, Cullinan Oncology's Total Assets are very stable compared to the past year. As of the 23rd of March 2025, Other Current Assets is likely to grow to about 16.5 M, while Debt To Assets are likely to drop 0.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.84 | 10.33 | |
| Tangible Book Value Per Share | 9.84 | 10.33 | |
| Enterprise Value Over EBITDA | (1.55) | (1.63) | |
| Price Book Value Ratio | 0.84 | 0.88 | |
| Enterprise Value Multiple | (1.55) | (1.63) | |
| Price Fair Value | 0.84 | 0.88 | |
| Enterprise Value | -78.7 M | -74.8 M |
Cullinan Oncology LLC benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cullinan Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cullinan Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cullinan Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cullinan Oncology Corporate Filings
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 21st of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Cullinan Oncology Earnings per Share Projection vs Actual
Cullinan Oncology Corporate Management
| Jennifer Michaelson | Chief Officer | Profile | |
| Kerry Whalen | Director Devel | Profile | |
| Jeffrey Trigilio | CFO Treasurer | Profile | |
| Mary Fenton | Chief Officer | Profile | |
| Jacquelyn JD | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.